Absolute lymphocyte recovery after autologous grafts of unmanipulated or CD34+-selected cells
. | Altes et al40 . | Rutella et al41 . | . | Divine et al11 . | Bomberger et al12 . | . | ||
|---|---|---|---|---|---|---|---|---|
. | CD34+-selected . | CD34+-selected . | Unmanipulated . | CD34+-selected . | CD34+-selected . | Unmanipulated . | ||
| Year | 2002 | 2000 | 1999 | 1998 | ||||
| No. of patients | 10 | 15 | 20 | 8 | 9 | 11 | ||
| CD34+ selected | Yes | Yes | No | Yes | Yes | No | ||
| Median age, y (range) | 50 (34-66) | 43 (18-59) | 40 (23-62) | 51 (47-59) | 41 (22-58) | 40 (28-60) | ||
| Diagnosis | NHL, CLL | MM, NHL | NHL | NHL | MM, NHL | |||
| CD34+ selection device | Isolex 300i + CD19+ depleted | Ceprate SC | Ceprate SC | Ceprate SC + FACS sorted | ||||
| Median CD34+ infused, × 106/kg (range) | 3.4 (1.5-11.7) | 4.6 (1.4-10.7) | 6.0 (1.5-20.5) | 4.6 (1.1-5.6) | 1.8 | NA | ||
| Median ALC, μL (range) | ||||||||
| At 1 mo | 810 (160-9400) | 410 (220-700) | 990 (730-1335) | 700* (100-2000) | NA | NA | ||
| At 3 mo | 1105 (377-3910) | 1050 (790-1480) | 1345 (1060-1845) | 350 (NA) | NA | NA | ||
| At 7 mo | 1250 (349-5310) | NA | NA | NA | NA | NA | ||
| At 12 mo | 1815† (800-3120) | NA | NA | 550 | NA | NA | ||
| Days to ALC more than 500 μL (range) | NA | 21 (16-23) | 19 (14-23) | NA | 130 (15-290) | 20 (10-170) | ||
. | Altes et al40 . | Rutella et al41 . | . | Divine et al11 . | Bomberger et al12 . | . | ||
|---|---|---|---|---|---|---|---|---|
. | CD34+-selected . | CD34+-selected . | Unmanipulated . | CD34+-selected . | CD34+-selected . | Unmanipulated . | ||
| Year | 2002 | 2000 | 1999 | 1998 | ||||
| No. of patients | 10 | 15 | 20 | 8 | 9 | 11 | ||
| CD34+ selected | Yes | Yes | No | Yes | Yes | No | ||
| Median age, y (range) | 50 (34-66) | 43 (18-59) | 40 (23-62) | 51 (47-59) | 41 (22-58) | 40 (28-60) | ||
| Diagnosis | NHL, CLL | MM, NHL | NHL | NHL | MM, NHL | |||
| CD34+ selection device | Isolex 300i + CD19+ depleted | Ceprate SC | Ceprate SC | Ceprate SC + FACS sorted | ||||
| Median CD34+ infused, × 106/kg (range) | 3.4 (1.5-11.7) | 4.6 (1.4-10.7) | 6.0 (1.5-20.5) | 4.6 (1.1-5.6) | 1.8 | NA | ||
| Median ALC, μL (range) | ||||||||
| At 1 mo | 810 (160-9400) | 410 (220-700) | 990 (730-1335) | 700* (100-2000) | NA | NA | ||
| At 3 mo | 1105 (377-3910) | 1050 (790-1480) | 1345 (1060-1845) | 350 (NA) | NA | NA | ||
| At 7 mo | 1250 (349-5310) | NA | NA | NA | NA | NA | ||
| At 12 mo | 1815† (800-3120) | NA | NA | 550 | NA | NA | ||
| Days to ALC more than 500 μL (range) | NA | 21 (16-23) | 19 (14-23) | NA | 130 (15-290) | 20 (10-170) | ||